• India business: 170 products & 15% of products in NLEM
    • Last 5 years new launches contribute 19% of sales; have been able to replace with newer portfolio | 90% of the new launches in specialty
    • Finding it tough to create bigger brands; still only 5 molecules in Top 300 (~ as 3 years ago)
    • Chronic now accounts for 67% of sales
  • US business: Acquisition of US-based Orit Laboratories LLC in October 2017 which has 11 fillings & 7 approvals- soft gelatin based oral solids and oral liquids
    • US front end crossed $ 100 million sales in the current year
    • Accounts for 77% of the international sales: So many fillings across the world not reaping dividends
  • Increased R&D strength to 900+
  • Manufacturing: Upcoming manufacturing units for general injectables and oncology injectables are on track and should be ready for exhibit batches by H1 2019.
  • Aleor Dermaceuticals Limited, the JV with Orbicular Pharmaceutical Technologies Private Limited, filed 3 ANDAs this year and has a strong planned pipeline of 45 products.